+1 #(S1 (S (NP (NP (NP (NP (JJ _PROT1_) (NN beta) (NN protein)) (PRN (-LRB- -LRB-) (NP (CD 25-35)) (-RRB- -RRB-))) (NN stimulation)) (PP (IN of) (NP (NP (NP (NP (NN _PROT2_) (NN A)) (, ,) (NP (NN C)) (CC and) (NP (NN D))) (NNS activities)) (PP (IN of) (NP (NN LA-N-2) (NNS cells))))))))
-1 #(S1 (S (LST (LS [3H) (-RRB- -RSB-)) (S (S (NP (NN Inositol) (JJ prelabeled) (NN LA-N-2) (NNS cells)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ varying) (NNS concentrations)) (PP (IN of) (NP (DT _PROT1_) (NN _PROT1_) (NN _PROT1_))))) (, ,) (PP (IN from) (NP (QP (CD 20) (TO to) (CD 125)) (NNS micrograms/ml)))))) (, ,) (CC and) (S (NP (NP (NN _PROT2_) (NN _PROT2_)) (NN activation)) (VP (VBD was) (VP (VBN measured)))))))
+1 #(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ adrenergic) (, ,) (NP (NP (JJ metabotropic) (NN amino) (NN acid)) (CC and) (NP (NN bombesin))) (NNS antagonists))) (PP (IN on) (NP (NP (DT the) (ADJP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_) (JJ mediated)) (NN stimulation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN activity)))))) (VP (VBD was) (VP (VBN investigated)))))
+1 #(S1 (S (S (NP (NP (NN Propranolol)) (, ,) (NP (NP (DT a) (NN beta) (JJ adrenergic) (NN antagonist)) (, ,) (NP (JJ 7-chloro-kynurenic) (NN acid))) (, ,) (NP (DT a) (JJ metabotropic) (NN amino) (NN acid) (NN antagonist)) (, ,) (CC and) (NP (NN [Tyr4-D-Phe12)) (-RRB- -RSB-) (NP (NN bombesin)) (, ,) (NP (DT a) (NN bombesin) (NN antagonist)) (, ,)) (VP (VBD blunted) (NP (NP (DT the) (NN _PROT1_) (NN _PROT1_) (NN _PROT1_) (NN stimulation)) (PP (IN of) (NP (NP (NN _PROT2_) (NN _PROT2_)) (NN activity))) (PP (IN in) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol)))))) (NP (JJ prelabeled) (NN LA-N-2) (NNS cells))))
+1 #(S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ _PROT1_) (NN beta) (NN protein) (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_)))) (VP (MD may) (VP (VB be) (NP (NP (NN receptor)) (VP (VBN mediated))))))))))
-1 #(S1 (S (NP (NP (DT The) (NN _PROT1_) (NN _PROT1_) (NN inhibitor)) (NP (NN U) (NN 71322))) (VP (VBD prevented) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_))) (PP (IN by) (NP (DT _PROT_) (NN _PROT_) (NN _PROT_)))))))
-1 #(S1 (S (NP (NP (DT The) (NN _PROT1_) (NN _PROT1_) (NN inhibitor)) (NP (NN U) (NN 71322))) (VP (VBD prevented) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT_) (NN _PROT_))) (PP (IN by) (NP (DT _PROT2_) (NN _PROT2_) (NN _PROT2_)))))))
+1 #(S1 (S (NP (NP (DT The) (NN _PROT_) (NN _PROT_) (NN inhibitor)) (NP (NN U) (NN 71322))) (VP (VBD prevented) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_))) (PP (IN by) (NP (DT _PROT2_) (NN _PROT2_) (NN _PROT2_)))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN _PROT1_) (NN secretion)) (CC and) (NP (NP (DT _PROT2_) (NN _PROT2_) (NN production)) (PP (IN in) (NP (NN NT2N) (NNS neurons))))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (DT the) (NN _PROT_) (NN _PROT_) (NN signal) (NN transduction) (NN pathway))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN _PROT1_) (NN secretion)) (CC and) (NP (NP (DT _PROT_) (NN _PROT_) (NN production)) (PP (IN in) (NP (NN NT2N) (NNS neurons))))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN signal) (NN transduction) (NN pathway))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN _PROT_) (NN secretion)) (CC and) (NP (NP (DT _PROT1_) (NN _PROT1_) (NN production)) (PP (IN in) (NP (NN NT2N) (NNS neurons))))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN signal) (NN transduction) (NN pathway))))))))))
-1 #(S1 (S (S (NP (NP (JJ Current) (NN interest)) (PP (IN in) (NP (NN reducing) (NN heart) (NN disease) (NNS risks))) (PP (IN by) (NP (NN diet)))) (VP (VBZ involves) (NP (NP (NN attention)) (PP (TO to) (NP (JJ total) (NN fat)))))) (: ;) (S (NP (NP (ADJP (ADJP (JJ saturated)) (, ,) (ADJP (JJ monounsaturated)) (, ,) (ADJP (JJ polyunsaturated)) (CC and) (ADJP (JJ trans))) (JJ fatty) (NNS acids)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ dietary) (NN _PROT1_)) (, ,) (NP (JJ soluble) (NN fiber)) (, ,) (NP (NN salt)) (, ,) (NP (NN alcohol))) (, ,) (NP (NNS antioxidants)) (, ,) (NP (JJ dietary) (NNS alterations))) (VP (VBG causing) (NP (NP (NP (NN homocysteinemia)) (CC and) (NP (JJ other) (JJ dietary) (NNS constituents))) (, ,) (NP (ADJP (JJ such) (PP (IN as) (NP (NP (NN _PROT2_) (NNS compounds)) (PP (IN in) (NP (DT some) (NN soy)))))) (NNS products)))))))
+1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ cAMP-dependent) (NN phosphorylation)) (PP (IN at) (NP (NP (DT a) (NN step)) (VP (VBG involving) (NP (JJ GTP-binding) (NN protein/PLC) (NN coupling)))))) (VP (MD can) (VP (VP (VB exert) (NP (DT a) (JJ negative) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN _PROT1_) (NN formation))) (PP (IN by) (NP (NN _PROT2_)))))) (CC and) (RB thereby) (VP (VB affect) (NP (NP (NN contraction/relaxation)) (PP (IN in) (NP (DT the) (NN myometrium))))))))))))
-1 #(S1 (S (NP (NP (NNS Roles)) (PP (IN of) (NP (NP (NN GTP)) (CC and) (NP (NN _PROT1_) (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion))) (PP (IN by) (NP (NN glucose))) (PP (IN in) (NP (NN rat) (JJ pancreatic) (NNS islets))))))))
-1 #(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (ADJP (NP (CD 98) (NN %)) (JJR greater)) (NN augmentation)) (PP (IN of) (NP (NN _PROT1_) (NN secretion))) (PP (IN by) (NP (ADJP (CD 16.7) (NN mM)) (NN glucose)))) (-LRB- -LRB-) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN diazoxide)) (CC and) (NP (ADJP (CD 40) (NN mM)) (NN K+)))))) (-RRB- -RRB-) (PP (IN in) (NP (JJ primed) (NNS islets))))) (: ;) (ADVP (RB however)) (, ,) (S (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ high) (NN glucose))) (S (VP (TO to) (VP (VB augment) (NP (NN _PROT2_) (NN activity)))))) (VP (VBD bore) (NP (DT no) (NN relationship)) (PP (TO to) (NP (DT the) (JJ secretory) (NN response)))))))
-1 #(S1 (S (S (NP (NN MPA)) (ADVP (RB markedly)) (VP (VBD inhibited) (NP (NN _PROT1_)) (PP (IN in) (NP (DT both) (NNS conditions))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NN _PROT2_) (NN secretion)) (VP (VBD was) (ADVP (RB only)) (VP (VBN inhibited) (PRN (-LRB- -LRB-) (PP (IN by) (NP (CD 46) (NN %))) (-RRB- -RRB-)) (PP (IN in) (NP (JJ primed) (NNS islets))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT2_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT2_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT1_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT2_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT1_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT1_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion)))))))))))))))
+1 #(S1 (S (NP (NP (NP (NN Regulation)) (PP (IN of) (NP (NN _PROT1_) (NN secretion))) (PP (IN via) (NP (NP (JJ ATP-sensitive) (NN K+) (NN channel)) (JJ independent) (NNS mechanisms)))) (: :) (NP (NP (NN role)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_)))))))
+1 #(S1 (S (NP (NP (DT The) (JJ further) (NN addition)) (PP (IN of) (NP (NP (NP (NN carbachol)) (, ,) (NP (NP (DT an) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VBZ activates) (NP (NP (DT an) (NN isozyme)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_))) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (VP (VBN activated) (PP (IN by) (NP (NN glucose)))))))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NN K+)))))))) (, ,) (NP (ADJP (CD 20) (NN mM)) (NN glucose)) (, ,) (CC plus) (NP (NN diazoxide))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ sustained) (NN amplification)) (PP (IN of) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (NP (NN mouse)) (CONJP (CC but) (RB not)) (NP (NN rat))) (NNS islets))))))))))
+1 #(S1 (S (NP (DT The) (NN inability) (S (VP (TO to) (VP (VB activate) (NP (NP (DT a) (ADJP (ADJP (JJ nutrient-)) (CC and) (ADJP (JJ calcium-regulated))) (NN _PROT1_) (NN _PROT1_) (NN isozyme)) (PP (IN in) (NP (NN mouse) (NNS islets))) (PP (TO to) (NP (NP (DT the) (JJ same) (NN extent)) (PP (IN as) (PP (IN in) (NP (NN rat) (NNS islets))))))))))) (VP (VBZ appears) (S (VP (TO to) (VP (VB account) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN for) (NP (DT these) (JJ different) (NN _PROT2_) (JJ secretory) (NNS responses))) (PP (IN under) (NP (DT these) (JJ unique) (NNS conditions)))))))))
-1 #(S1 (S (ADVP (RB Further)) (, ,) (NP (NP (DT the) (JJ _PROT1_) (NN activation)) (PP (IN of) (NP (NP (NN IK)) (PRN (-LRB- -LRB-) (NP (NN sl)) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RB effectively)) (VP (VBN antagonized) (PP (PP (IN by) (NP (NP (QP (QP (CD 5) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -8)) (-RRB- -RRB-))) (NN mol/l) (NN U-73122)) (CC or) (NP (NP (QP (QP (CD 5) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -6)) (-RRB- -RRB-))) (NN mol/l) (NN 2-nitro-4-carboxyphenyl) (NN N)) (, ,) (NP (NP (NN N-diphenylcarbamate)) (PRN (-LRB- -LRB-) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN cell) (NN membrane) (NN phospholipase) (NN C)))) (-RRB- -RRB-)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (ADJP (RB intracellularly) (VBN applied)) (NN heparin)))))) (PRN (-LRB- -LRB-) (NP (NP (JJ selective) (NN inhibitor)) (PP (IN of) (NP (ADJP (NN _PROT2_) (-LRB- -LRB-) (NN IP3) (-RRB- -RRB-) (JJ -induced)) (NN Ca2+) (NN release) (NNS channels)))) (-RRB- -RRB-))))
-1 #(S1 (S (NP (NP (DT The) (NNS data)) (VP (VBN obtained))) (VP (VBP suggest) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (PP (IN that) (S (NP (JJ selective) (NN _PROT1_) (NNS receptors)) (VP (VBP are) (ADJP (JJ present) (PP (IN on) (NP (NP (DT the) (NNS membranes)) (PP (IN of) (NP (JJ guinea-pig) (JJ antral) (NN smooth) (NN muscle) (NNS cells))))))))) (, ,) (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (PP (IN that) (S (S (NP (DT the) (JJ oxytocin-related) (NN relaxation)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -sensitive)) (NN K+) (NN conductivity))))) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ _PROT2_) (NN release)) (PP (IN of) (NP (NN Ca2+))) (PP (IN from) (NP (NP (DT the) (JJ submembrane) (JJ located) (NNS cisternae)) (PP (IN of) (NP (NP (DT the) (JJ sarcoplasmic) (NN reticulum)) (NN Ca2+) (NNS stores)))))))))))) (CC and) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (PP (IN in) (NP (NN turn))) (, ,) (NP (DT this)) (VP (VBZ evokes) (NP (NP (DT a) (JJ non-inactivating) (NN component)) (PP (IN of) (NP (NN IK)))) (, ,) (S (VP (VBG hyperpolarizing) (NP (DT the) (NN cell) (NN membrane))))))))))))
+1 #(S1 (S (NP (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (JJ potent) (NNS antioxidants)) (, ,) (PP (JJ such) (IN as) (NP (NNS _PROT1_))) (, ,)) (VP (VP (VB protect) (NP (NP (NN MM-LDL)) (PP (IN from) (NP (NN lipoperoxidation))))) (CC and) (VP (VB preserve) (NP (PRP$ their) (NN ability) (S (VP (TO to) (ADVP (RB efficiently)) (VP (VB deliver) (NP (NN _PROT2_)) (PP (TO to) (NP (NNS cells))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT2_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT2_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT1_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT1_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative))))))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN _PROT1_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN by) (NP (NNS TZDs))) (PP (IN in) (NP (DT the) (VBD WAT) (NP (CC and) (NP (NN BAT)) (PP (IN in) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT an) (JJ obese) (NN model)) (PP (IN with) (NP (NN _PROT2_) (NN receptor) (NN defect))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN adipose) (NN _PROT_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS TZDs))))) (ADVP (FW in) (FW vitro))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN _PROT1_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN by) (NP (NNS TZDs))) (PP (IN in) (NP (DT the) (VBD WAT) (NP (CC and) (NP (NN BAT)) (PP (IN in) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT an) (JJ obese) (NN model)) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN adipose) (NN _PROT2_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS TZDs))))) (ADVP (FW in) (FW vitro))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN _PROT_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN by) (NP (NNS TZDs))) (PP (IN in) (NP (DT the) (VBD WAT) (NP (CC and) (NP (NN BAT)) (PP (IN in) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT an) (JJ obese) (NN model)) (PP (IN with) (NP (NN _PROT1_) (NN receptor) (NN defect))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN adipose) (NN _PROT2_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS TZDs))))) (ADVP (FW in) (FW vitro))))))))))
+1 #(S1 (S (S (NP (NP (VBN Enhanced) (JJ phosphoinositide) (NN hydrolysis)) (PP (IN via) (NP (NP (NN overexpression)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_) (NN beta1) (NN or) (NN delta1)))))) (VP (VBZ inhibits) (NP (NP (JJ stimulus-induced) (NN _PROT2_) (NN release)) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells)))))) (. .)))
-1 #(S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (VBN enhanced) (JJ phosphoinositide) (NN hydrolysis))) (PP (IN on) (NP (NN _PROT1_) (NN secretion))))))) (, ,) (NP (NP (NP (JJ phosphoinositide-specific) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLCbeta1)) (-RRB- -RRB-))) (CC or) (NP (NN _PROT_))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells))) (PP (IN via) (NP (JJ adenoviral) (NNS vectors)))))) (. .)))
-1 #(S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (VBN enhanced) (JJ phosphoinositide) (NN hydrolysis))) (PP (IN on) (NP (NN _PROT1_) (NN secretion))))))) (, ,) (NP (NP (NP (JJ phosphoinositide-specific) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN PLCbeta1)) (-RRB- -RRB-))) (CC or) (NP (NN _PROT2_))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells))) (PP (IN via) (NP (JJ adenoviral) (NNS vectors)))))) (. .)))
-1 #(S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (VBN enhanced) (JJ phosphoinositide) (NN hydrolysis))) (PP (IN on) (NP (NN _PROT_) (NN secretion))))))) (, ,) (NP (NP (NP (JJ phosphoinositide-specific) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PLCbeta1)) (-RRB- -RRB-))) (CC or) (NP (NN _PROT2_))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells))) (PP (IN via) (NP (JJ adenoviral) (NNS vectors)))))) (. .)))
+1 #(S1 (S (NP (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP (NN PKABA1)))) (ADVP (RB drastically)) (VP (VBD suppressed) (NP (NP (NN expression)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ low-)) (CC and) (ADJP (JJ high-pI))) (NP (NP (NN _PROT1_)) (CC and) (NP (NN protease))) (NNS genes)) (VP (VBN induced) (PP (IN by) (NP (NN _PROT2_))))))))))
+1 #(S1 (S (NP (NP (JJ Long-term) (NNS changes)) (PP (IN in) (NP (NP (NN gastrin)) (, ,) (NP (NN cholecystokinin)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NN response) (TO to) (NP (NN _PROT2_) (NN treatment))))))
+1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ repeated) (NNS injections)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBP influence) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (ADJP (RB vagally) (VBN controlled)) (NNS hormones)) (PP (JJ such) (IN as) (NP (NP (NN gastrin)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN somatostatin)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ endogenous) (NN _PROT_)) (CC and) (NP (NN glucose)))))))))))))))
-1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ repeated) (NNS injections)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBP influence) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (ADJP (RB vagally) (VBN controlled)) (NNS hormones)) (PP (JJ such) (IN as) (NP (NP (NN gastrin)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN somatostatin)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ endogenous) (NN _PROT2_)) (CC and) (NP (NN glucose)))))))))))))))
-1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ repeated) (NNS injections)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBP influence) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (ADJP (RB vagally) (VBN controlled)) (NNS hormones)) (PP (JJ such) (IN as) (NP (NP (NN gastrin)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT1_)) (CC and) (NP (NN somatostatin)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ endogenous) (NN _PROT2_)) (CC and) (NP (NN glucose)))))))))))))))
+1 #(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CC both) (NP (NN _PROT1_)) (CC and) (NP (NN CCK))) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN _PROT2_) (NN treatment))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (NP (QP (CD 3) (CC and) (CD 10)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (NN injection)) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (: ;) (NP (NN _PROT_) (NN p) (NN <) (CD 0.01)) (, ,) (NP (NN CCK) (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)))))))))))
-1 #(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CC both) (NP (NN _PROT1_)) (CC and) (NP (NN CCK))) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN _PROT_) (NN treatment))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (NP (QP (CD 3) (CC and) (CD 10)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (NN injection)) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (: ;) (NP (NN _PROT2_) (NN p) (NN <) (CD 0.01)) (, ,) (NP (NN CCK) (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)))))))))))
-1 #(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CC both) (NP (NN _PROT_)) (CC and) (NP (NN CCK))) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN _PROT1_) (NN treatment))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (NP (QP (CD 3) (CC and) (CD 10)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (NN injection)) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (: ;) (NP (NN _PROT2_) (NN p) (NN <) (CD 0.01)) (, ,) (NP (NN CCK) (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ alpha2-adrenoreceptor) (NN agonist) (NN clonidine)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN microgram/kg) (NN intracerebroventricularly)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 3) (NNS days)) (IN after) (NP (DT the) (JJ 5-day) (NN treatment) (NN period))) (PP (IN with) (NP (NP (NN _PROT1_)) (CC or) (NP (NN saline)))))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC and) (NP (NN CCK))))) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ _PROT_) (NNS rats)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS controls)) (VP (VBG receiving) (NP (NP (NN clonidine)) (ADVP (RB only)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ alpha2-adrenoreceptor) (NN agonist) (NN clonidine)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN microgram/kg) (NN intracerebroventricularly)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 3) (NNS days)) (IN after) (NP (DT the) (JJ 5-day) (NN treatment) (NN period))) (PP (IN with) (NP (NP (NN _PROT1_)) (CC or) (NP (NN saline)))))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN CCK))))) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ _PROT2_) (NNS rats)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS controls)) (VP (VBG receiving) (NP (NP (NN clonidine)) (ADVP (RB only)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ alpha2-adrenoreceptor) (NN agonist) (NN clonidine)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN microgram/kg) (NN intracerebroventricularly)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 3) (NNS days)) (IN after) (NP (DT the) (JJ 5-day) (NN treatment) (NN period))) (PP (IN with) (NP (NP (NN _PROT_)) (CC or) (NP (NN saline)))))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN CCK))))) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ _PROT2_) (NNS rats)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS controls)) (VP (VBG receiving) (NP (NP (NN clonidine)) (ADVP (RB only)))))))))))
+1 #(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT these) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ induces) (NP (NP (JJ long-lasting) (NNS changes)) (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN gastrin)) (, ,) (NP (NN CCK)) (CC and) (NP (NN _PROT2_))))))) (, ,) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NP (NN somatostatin)) (CC or) (NP (NN glucose))) (NNS levels)))))))))))
-1 #(S1 (S (NP (NP (NN Plasma) (NN _PROT1_)) (, ,) (CC and) (NP (NP (DT some) (ADJP (RB functionally) (JJ related)) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NP (NN CCK)) (, ,) (NP (NN gastrin)) (, ,) (NP (NN somatostatin)) (CC and) (NP (NN _PROT2_))) (-RRB- -RRB-))) (, ,)) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (JJ standard) (NN radioimmunoassay) (NNS techniques)))))))
+1 #(S1 (S (NP (NP (DT The) (JJ _PROT1_) (NNS elements)) (VP (VBN conserved) (PP (IN in) (NP (JJ cereal) (NN _PROT2_) (NNS genes))))) (VP (VBP are) (RB not) (VP (VBN included) (PP (IN in) (NP (NP (DT the) (JJ 5'-upstream) (NN region)) (PP (IN of) (NP (NP (NN Rep1)) (CC or) (NP (NN RepA))))))))))
-1 #(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (, ,) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN mitogen) (JJ activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NN kinase)) (ADVP (RB alone))))) (VP (VBZ is) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB promote) (NP (NN _PROT1_) (NN secretion))))))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MAP) (NN kinase)))) (VP (MD will) (VP (VB reduce) (NP (NN _PROT2_) (NN secretion)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (NP (NN _PROT_) (NN _PROT_)) (CC or) (NP (NN phosphatidylinositol) (NN 3-kinase))) (VP (VBP are) (ADVP (RB additionally)) (VP (VBN inhibited))))))))))
-1 #(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (, ,) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN mitogen) (JJ activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NN kinase)) (ADVP (RB alone))))) (VP (VBZ is) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB promote) (NP (NN _PROT1_) (NN secretion))))))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MAP) (NN kinase)))) (VP (MD will) (VP (VB reduce) (NP (NN _PROT_) (NN secretion)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (NP (NN _PROT2_) (NN _PROT2_)) (CC or) (NP (NN phosphatidylinositol) (NN 3-kinase))) (VP (VBP are) (ADVP (RB additionally)) (VP (VBN inhibited))))))))))
-1 #(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (, ,) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN mitogen) (JJ activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NN kinase)) (ADVP (RB alone))))) (VP (VBZ is) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB promote) (NP (NN _PROT_) (NN secretion))))))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MAP) (NN kinase)))) (VP (MD will) (VP (VB reduce) (NP (NN _PROT1_) (NN secretion)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (NP (NN _PROT2_) (NN _PROT2_)) (CC or) (NP (NN phosphatidylinositol) (NN 3-kinase))) (VP (VBP are) (ADVP (RB additionally)) (VP (VBN inhibited))))))))))
+1 #(S1 (S (NP (NP (NN Tolbutamide)) (CC and) (NP (NN diazoxide))) (VP (VBP modulate) (NP (NP (NP (NP (NP (NN _PROT1_) (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN signaling)) (CC and) (NP (NN _PROT2_) (NN secretion))) (PP (IN in) (NP (NNS beta-cells)))))))
-1 #(S1 (S (NP (PRP We)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide)) (, ,) (SBAR (WHNP (WDT which)) (S (ADJP (ADJP (JJ close)) (CC or) (ADJP (JJ open)) (NP (NP (NP (NP (JJ ATP-sensitive) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NN K) (-LRB- -LRB-) (NN ATP) (-RRB- -RRB-) (NNS channels)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP interact) (PP (PP (IN with) (NP (NP (NP (NP (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS signals)) (PP (IN in) (NP (NN HIT-T15) (CC and) (NN mouse) (NNS beta-cells))))) (CC and) (PP (IN with) (NP (NP (JJ _PROT2_) (NN _PROT_) (NN secretion)) (PP (IN from) (NP (NN HIT-T15) (NNS cells))))))))))))
-1 #(S1 (S (NP (PRP We)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide)) (, ,) (SBAR (WHNP (WDT which)) (S (ADJP (ADJP (JJ close)) (CC or) (ADJP (JJ open)) (NP (NP (NP (NP (JJ ATP-sensitive) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NN K) (-LRB- -LRB-) (NN ATP) (-RRB- -RRB-) (NNS channels)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP interact) (PP (PP (IN with) (NP (NP (NP (NP (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS signals)) (PP (IN in) (NP (NN HIT-T15) (CC and) (NN mouse) (NNS beta-cells))))) (CC and) (PP (IN with) (NP (NP (JJ _PROT_) (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NN HIT-T15) (NNS cells))))))))))))
+1 #(S1 (S (NP (PRP We)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide)) (, ,) (SBAR (WHNP (WDT which)) (S (ADJP (ADJP (JJ close)) (CC or) (ADJP (JJ open)) (NP (NP (NP (NP (JJ ATP-sensitive) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NN K) (-LRB- -LRB-) (NN ATP) (-RRB- -RRB-) (NNS channels)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP interact) (PP (PP (IN with) (NP (NP (NP (NP (JJ _PROT_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS signals)) (PP (IN in) (NP (NN HIT-T15) (CC and) (NN mouse) (NNS beta-cells))))) (CC and) (PP (IN with) (NP (NP (JJ _PROT1_) (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NN HIT-T15) (NNS cells))))))))))))
+1 #(S1 (S (ADVP (RB Thus)) (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide))) (VP (VBP regulate) (NP (NP (CC both) (NP (NP (NP (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN signaling)) (CC and) (NP (NN _PROT2_) (NN secretion))) (PP (IN from) (NP (JJ pancreatic) (NNS beta-cells)))) (PP (IN by) (S (VP (VBG modulating) (NP (NP (NP (NN K)) (PRN (-LRB- -LRB-) (NP (NN ATP)) (-RRB- -RRB-))) (NNS channels))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG determining) (NP (JJ voltage-sensitive) (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (NN influx)))))))
-1 #(S1 (S (NP (PRP We)) (VP (VBD examined) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (PP (IN in) (NP (NP (NP (JJ young) (NNS men) (NNS effects)) (PP (IN of) (NP (NP (JJ intravenous) (NNS injections)) (PP (IN of) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 4x50) (CC or) (CD 100)) (NN microg)) (, ,) (S (NP (NN n)) (VP (JJ =) (NP (CD 9) (CC and) (CD 11)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN at) (NP (NP (CD 22.00)) (, ,) (NP (CD 23.00)) (, ,) (NP (CD 24.00)) (CC and) (NP (CD 01.00))))))) (VP (VBN compared) (PP (TO to) (NP (NN saline))))) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (DT the) (JJ sleep) (NN electroencephalogram)) (PRN (-LRB- -LRB-) (NP (NN EEG)) (: ;) (S (VP (VBN recorded) (PP (IN from) (NP (CD 23.00) (TO to) (CD 07.00))))) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ nocturnal) (NN secretion)) (PP (IN of) (NP (NP (NP (JJ adrenocorticotrophic) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN ACTH)) (-RRB- -RRB-))) (, ,) (NP (NN cortisol)) (, ,) (NP (NP (NN growth) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN GH)) (-RRB- -RRB-))) (, ,) (NP (NN prolactin)) (CC and) (NP (NN _PROT2_))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN T3)) (VP (MD may) (VP (VB increase) (NP (NP (NN _PROT1_) (NN family) (NN expression)) (ADJP (JJ independent) (PP (IN of) (NP (NN _PROT2_) (NN action))))))))))))
+1 #(S1 (S (NP (NP (NP (NN _PROT1_) (NNS effects)) (PP (IN on) (NP (NP (JJ pulsatile) (NN gonadotropin) (VBG releasing) (NN hormone) (NN secretion)) (PP (IN from) (NP (DT the) (JJ adult) (NN rat) (NN hypothalamus)))))) (CC and) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (NP (NN cocaine)) (CC and) (NP (NN amphetamine))) (NP (NP (VBN regulated) (NN transcript) (NN peptide)) (CC and) (NP (NN _PROT2_) (NN _PROT2_))))))) (VP (VBP [In) (NP (NN Process) (NP (NNP Citation)))) (-RRB- -RSB-)))
+1 #(S1 (S (S (NP (NN _PROT1_)) (VP (MD may) (VP (VB act) (PP (IN as) (NP (NP (DT a) (JJ negative) (NN feedback) (NN signal)) (PP (TO to) (NP (NP (DT the) (JJ hypothalamic) (NN control)) (PP (IN of) (NP (NN appetite))))))) (PP (IN through) (NP (NP (NP (NN suppression)) (PP (IN of) (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (NN secretion)))) (CC and) (NP (NP (NN stimulation)) (PP (IN of) (NP (NP (NN cocaine)) (CC and) (NP (NP (NN amphetamine) (JJ regulated) (NN transcript)) (PRN (-LRB- -LRB-) (NP (NN CART)) (-RRB- -RRB-))))))))))) (. .)))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBD aimed) (PP (IN at) (S (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NN CART)) (CC and) (NP (NN _PROT2_)))) (PP (IN on) (NP (NP (DT the) (JJ hypothalamic) (NN control)) (PP (IN of) (NP (DT the) (JJ pituitary-gonadal) (NN system))))))))))) (. .)))
-1 #(S1 (S (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (NN GnRH) (NN pulse) (NN amplitude))) (VP (VBN caused) (PP (IN by) (NP (NN _PROT1_))))) (VP (VBD was) (ADVP (RB totally)) (VP (VBN prevented) (PP (IN by) (NP (NP (NN coincubation)) (PP (IN with) (NP (NP (DT an) (JJ anti-CART) (NN antiserum)) (SBAR (IN whereas) (S (NP (PRP it)) (VP (VBD was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN coincubation)) (PP (IN with) (NP (NP (DT the) (NN _PROT2_) (JJ Y5-receptor) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -7) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-))))))))))))))))) (. .)))
-1 #(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (VP (VBP show) (NP (NP (JJ separate) (JJ permissive) (NNS effects)) (PP (IN on) (NP (NP (NN GnRH) (NN secretion)) (PP (IN in) (NP (DT the) (JJ adult) (NN rat) (NN hypothalamus)))))))) (. .)))
+1 #(S1 (S (NP (NP (DT The) (NN induction)) (PP (IN of) (NP (NN _PROT1_))) (VP (VBN triggered) (PP (IN by) (NP (JJ _PROT2_) (NN _PROT2_))) (PP (IN in) (NP (JJ barley) (NNS embryos))))) (VP (VBZ is) (VP (VBN repressed) (PP (IN by) (NP (NNS sugars)))))))
-1 #(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN glucose)) (VP (VBZ represses) (NP (NN _PROT1_) (NN signalling)) (ADVP (RB late)) (PP (IN along) (NP (DT this) (NN hormone) (NN transduction) (NN pathway))) (, ,) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ _PROT2_) (JJ transcriptional) (NN activator)) (PRN (-LRB- -LRB-) (NP (NN GAMYB)) (-RRB- -RRB-))))))) (VP (VBN needed) (PP (IN for) (NP (NN _PROT_) (NN induction))))))))))
-1 #(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN glucose)) (VP (VBZ represses) (NP (NN _PROT1_) (NN signalling)) (ADVP (RB late)) (PP (IN along) (NP (DT this) (NN hormone) (NN transduction) (NN pathway))) (, ,) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ _PROT_) (JJ transcriptional) (NN activator)) (PRN (-LRB- -LRB-) (NP (NN GAMYB)) (-RRB- -RRB-))))))) (VP (VBN needed) (PP (IN for) (NP (NN _PROT2_) (NN induction))))))))))
-1 #(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN glucose)) (VP (VBZ represses) (NP (NN _PROT_) (NN signalling)) (ADVP (RB late)) (PP (IN along) (NP (DT this) (NN hormone) (NN transduction) (NN pathway))) (, ,) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ _PROT1_) (JJ transcriptional) (NN activator)) (PRN (-LRB- -LRB-) (NP (NN GAMYB)) (-RRB- -RRB-))))))) (VP (VBN needed) (PP (IN for) (NP (NN _PROT2_) (NN induction))))))))))
